תבנית:תרופה/היקמטין 0.25 מ"ג - Hycamtin 0.25 mg

× ×ª×× × ×ª×¨××¤×

×××¨×©×

××× ×× ×× × ××¡×¤××	×××§×××× 1 ×"× - Hycamtin 1 mg ×××§×××× IV - Hycamtin iv
×§×××¦× ×¤×¨××§××××××ª (ATC4)	L01XX Other antineoplastic agents
××¨××× ×¤×¢×× (ATC5)	*Topotecan AS HYDROCHLORIDE 0.25MG âL01XX17 Topotecan AS HYDROCHLORIDE 0.25MG âL01XX17 Other antineoplastic agents L01XX âL01XX17 Strada provinciale asolana n.90,san polo di torille, 43056, PARMA, ITALY âL01XX17 Topotecan AS HYDROCHLORIDE 0.25MG âL01XX17
×¦××¨×ª ××ª×	PER OS
×¦××¨×ª ××× ××	HARD GELATIN CAPSULES
××ª××××	Indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.
×ª×× ××ª:× ×ª×× × ×¡×/×ª×¨××¤×/×××§×××× 0.25 ×"× - Hycamtin 0.25 mg
××ª×××ª ××× ××	Posology and method of administration
××ª×××××ª × ××	Contraindications
×ª××¤×¢××ª ×××××	Undesirable effects
×ª×××××ª ××× ×ª×¨××¤×ª×××ª	Interaction with other medicinal products and other forms of interaction
×©××××© ××××¨××× ××× ×§×	Pregnancy and Lactation
×¤×¨××§×××× ×××§×	Pharmacodynamic Properties
×¤×¨××§××§×× ×××§×	Pharmacokinetic Properties
×¢××× ××¨××¤× ×××××¨××ª ××¢×××	×¢××× ××¨××¤× ××××¨× ××¢×××

×¢××× ××¦×¨××	*×¢××× ××¦×¨×× ×¢××× ××¦×¨×× ×¢××× ××¦×¨××

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×××§×××× 0.25 ×"× Â® ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	-
××××¢ ××¨×©×ª	-
×©× ××¦×¨×	GLAXO SMITH KLINE MANUFACTURING S.P.A., ITALY
×©× ××¢× ××¨××©××	NOVARTIS ISRAEL LTD
×¨××©×××	×ª××¨×× ×××©×: 06/2008. ×¨××©××× ××ª××¨××: 07/2014
×ª××¨×× ×¢×××× ×××¨××	27/08/17

××£ ×× × ××¦×¨ ×¢× ××× ××× ××××××¨ ×ª×× ××ª ×¢× ×¤×¨×× ××ª×¨××¤×.

{{×ª×¨××¤×/×××§×××× 0.25 ×"× - Hycamtin 0.25 mg}}

×:

{{×ª×¨××¤×/×××§×××× 0.25 ×"× - Hycamtin 0.25 mg
| ×©× ××¤×¨×××¨=×¢×¨× ×××© (×××¨×¡ ××ª ××¢×¨× ×©×××× ×××××¨)
}}

השינוי האחרון נעשה בֹ־27 באוגוסט 2017 ב־15:04

ויקיתרופות